TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19115911

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE) for 6 to 7 consecutive days (2-h ambient PO2=90 mmHg sedentary and 1-h ambient PO2=110 mmHg exercising at 80+/‐5% of maximum heart rate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SHAM treatment for 6 to 7 consecutive days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both IHE and SHAM groups
Number of subjects: 16
Study: 18396244

Group type: EXPERIMENTAL
Intervention: Antidepressant users (36.2% of participants, n = 50)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Other prescription medications
Number of subjects: 138
Study: 15466607

Group type: EXPERIMENTAL
Intervention: Recall of distant poor team outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good team outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negotiation task measures obtained immediately or at a later time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Team performance on an investment task
Number of subjects: 0
Study: 11725980

Group type: EXPERIMENTAL
Intervention: Multipurpose solution with HPMC
Number of subjects: 147
Study: 9227246

Group type: EXPERIMENTAL
Intervention: Contrast enhanced 3D MP‐RAGE
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 3D CISS
Number of subjects: 38
Study: 8384232

Group type: EXPERIMENTAL
Intervention: 0.1% RA cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.001% RA cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% SDS in RA vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study: 3609120

Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg daily for 1 week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31829133

Group type: EXPERIMENTAL
Intervention: Fall prevention decision tool implementation in general practice
Number of subjects: 560
Study: 28347690

Group type: EXPERIMENTAL
Intervention: Nordic Walking Group (NWG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Walking Group without poles (WG)
Number of subjects: 42
Study: 26453120

Group type: EXPERIMENTAL
Intervention: Diet and exercise lifestyle intervention (six visits to a dual qualified dietitian/exercise physiologist)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Attention control (scheduled telephone contact)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Diet and exercise lifestyle intervention
Number of subjects: 119
Study: 23932463

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/d
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg/d
Number of subjects: 92

Group type: COMPARATOR
Intervention: Valsartan 80 mg/d
Number of subjects: 92
Study: 20974292

Group type: EXPERIMENTAL
Intervention: Web-based intervention for improving provider knowledge about strabismus and amblyopia (S/A) and preschool vision screening (PVS)
Number of subjects: 8590

Group type: COMPARATOR
Intervention: Control group (blood pressure intervention)
Number of subjects: 8590
Study: 19593972

Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (non-stimulation)
Number of subjects: 64
Study: 16445332

Group type: EXPERIMENTAL
Intervention: Cued gait training with visual cues (initially 110% of uncued step length, later increased to 120%) for 4 weeks
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Cued gait training with visual cues
Number of subjects: 1

Group type: COMPARATOR
Intervention: Uncued gait training
Number of subjects: 1
Study: 14504090

Group type: EXPERIMENTAL
Intervention: Itraconazole (intravenous 200 mg daily, or oral solution 2.5 mg/kg 3 times daily)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Fluconazole (intravenous or oral, 400 mg daily)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) conditioning with itraconazole
Number of subjects: 197
Study: 11342474

Group type: EXPERIMENTAL
Intervention: High concentrations of circulating IL-6 in patients with small aneurysms
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: IL-6 genotype (‐174 G‐‐>C polymorphism)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: GG genotype
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: IL-6 concentration in iliac arteries
Number of subjects: 485
Study: 9412794

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg tid
Number of subjects: 104

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 104
Study: 8433078

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Apo E 3/3 phenotype
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epsilon 2-allele
Number of subjects: 120

Group type: COMPARATOR
Intervention: Apo E phenotype
Number of subjects: 120
Study: 3625473

Group type: EXPERIMENTAL
Intervention: Computer breakdown condition
Number of subjects: 62

Group type: COMPARATOR
Intervention: Interruption condition
Number of subjects: 62

Group type: COMPARATOR
Intervention: No-interruption condition
Number of subjects: 62
Study: 30203762

Group type: EXPERIMENTAL
Intervention: Ibandronate needle therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Zoledronic acid needle therapy
Number of subjects: 100
Study: 27344665

Group type: COMPARATOR
Intervention: Piribedil (150–300 mg/day, three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piribedil
Number of subjects: 0
Study: 24684104

Group type: EXPERIMENTAL
Intervention: TEAS + GA
Number of subjects: 40

Group type: COMPARATOR
Intervention: GA control
Number of subjects: 40
Study: 22290206

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 80
Study: 20185361

Group type: EXPERIMENTAL
Intervention: Historical‐objective‐distribution based scale (Hi‐Ob‐Db)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historical‐objective scale (Hi‐Ob)
Number of subjects: 100
Study: 18397687

Group type: EXPERIMENTAL
Intervention: Serlift (50 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zoloft (50 mg)
Number of subjects: 24
Study: 15653032

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 202
Study: 12371727

Group type: EXPERIMENTAL
Intervention: Ultrafiltration at 20 ml/h-1/kg-1 (group 1, n = 146)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Ultrafiltration at 35 ml/h-1/kg-1 (group 2, n = 139)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Ultrafiltration at 45 ml/h-1/kg-1 (group 3, n = 140)
Number of subjects: 425
Study: 9666415

Group type: COMPARATOR
Intervention: Leflunomide 25 mg once daily
Number of subjects: 402

Group type: COMPARATOR
Intervention: Leflunomide 10 mg daily
Number of subjects: 402

Group type: COMPARATOR
Intervention: Leflunomide 10 mg and 25 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 402
Study: 8033588

Group type: EXPERIMENTAL
Intervention: HIR-CAL grid-modified keratometer
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mengher-Tonge xeroscope
Number of subjects: 45
Study: 2688186

Group type: EXPERIMENTAL
Intervention: HR capsules (1,200 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 31502736

Group type: EXPERIMENTAL
Intervention: Varenicline (Quit2Live trial)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Varenicline (PNAT trial)
Number of subjects: 870
Study: 29427081

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27711100

Group type: EXPERIMENTAL
Intervention: ALOKA end fire probe (size 74 mm)
Number of subjects: 114

Group type: COMPARATOR
Intervention: B‐K Type 8818 probe (size 58 mm)
Number of subjects: 114
Study: 24796978

Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR) exercise during warm-up
Number of subjects: 16

Group type: COMPARATOR
Intervention: Free Weight Resistance (FWR) exercise during warm-up
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR) exercise
Number of subjects: 16
Study: 23033982

Group type: EXPERIMENTAL
Intervention: aVQ (abnobaVISCUM(®) Quercus) injected subcutaneously three times per week from postoperative day 7 to week 24
Number of subjects: 32

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 32
Study: 20614484

Group type: EXPERIMENTAL
Intervention: EUS followed by ERCP under conscious sedation
Number of subjects: 54

Group type: COMPARATOR
Intervention: EUS only (Control Group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: ERCP only (Control Group C)
Number of subjects: 54
Study: 18979342

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the medial gastrocnemius muscle after acute passive stretching
Number of subjects: 12
Study: 15837249

Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (bare-metal EXPRESS stent)
Number of subjects: 170
Study: 12457672

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 107

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall incidence of PONV
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Topical and retrobulbar anesthesia
Number of subjects: 107
Study: 10845347

Group type: EXPERIMENTAL
Intervention: Quality of social support (appraisal, belonging, tangible)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Interpersonal Support Evaluation List (quantitative support and esteem subscale)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Measures of qualitative and quantitative social support
Number of subjects: 103
Study: 8731496

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group (group discussion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 60
Study: 1564703

Group type: EXPERIMENTAL
Intervention: Early luteal phase progesterone supplementation (group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard protocol progesterone supplementation after embryo transfer (group C)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Higher progesterone levels from early luteal phase through embryo transfer (group A)
Number of subjects: 72
Study: 3901934

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (high sodium isotonic fluid at 40 ml/kg per hour during rehydration phase, low sodium isotonic fluid during maintenance phase)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Intravenous fluid therapy
Number of subjects: 470
Study: 31699150

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg, p.o. q.d.) plus gefitinib (250 mg, p.o. q.d.)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 310
Study: 29897440

Group type: EXPERIMENTAL
Intervention: Annual mass azithromycin distribution
Number of subjects: 240

Group type: COMPARATOR
Intervention: Biannual mass azithromycin distribution
Number of subjects: 240
Study: 27362585

Group type: EXPERIMENTAL
Intervention: Arterial spin labelling (ASL) MRI
Number of subjects: 41
Study: 25293478

Group type: EXPERIMENTAL
Intervention: Etomidate induction (group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane induction (group S)
Number of subjects: 60
Study: 22323414

Group type: EXPERIMENTAL
Intervention: Short-term T1D group
Number of subjects: 16
Study: 20137094

Group type: EXPERIMENTAL
Intervention: MIS-TKA (Minimal Invasion Surgery)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 62
Study: 17671066

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray (5 mg)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 15616064

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate 0.1 mg.kg(‐1).min(‐1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 0.9% NaCl (Control)
Number of subjects: 29
Study: 11314774

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Selegiline (after reinstitution)
Number of subjects: 9
Study: 9150864

Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.3% tobramycin
Number of subjects: 30
Study: 7951338

Group type: EXPERIMENTAL
Intervention: Local radiotherapy of 18-20 Gy to the testis
Number of subjects: 1810

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 1810

Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1810
Study: 2959208

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 2108911

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole plus colistin with nonabsorbable antimycotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin with nonabsorbable antimycotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole plus colistin and ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study: 1080266

Group type: EXPERIMENTAL
Intervention: 0.2 mg methylergonovine maleate (Methergine) intramuscularly
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study: 31068125

Group type: EXPERIMENTAL
Intervention: Message 1 (depression can happen to anyone)
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Message 2 (depression needs treatment)
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Message 3 (depression improves with treatment)
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Emotional responses to Message 2
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Emotional responses to Message 3
Number of subjects: 1957
Study: 28182335

Group type: EXPERIMENTAL
Intervention: Ductus venosus (DV) monitoring
Number of subjects: 317

Group type: COMPARATOR
Intervention: CTG-STV monitoring
Number of subjects: 317
Study: 26050057

Group type: EXPERIMENTAL
Intervention: Arm blood pressure measurement at 0° backrest elevation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ankle blood pressure measurement at 0° backrest elevation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arm blood pressure measurement at 30° backrest elevation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ankle blood pressure measurement at 30° backrest elevation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diastolic BP correlation for participants without ankle edema
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diastolic BP correlation for participants with ankle edema
Number of subjects: 30
Study: 23182660

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 211
Study: 21722898

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19381735

Group type: EXPERIMENTAL
Intervention: Probiotics (2.4 billion colonies of Lactobacillus administered daily postoperatively)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 16769056

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 14679122

Group type: EXPERIMENTAL
Intervention: Irinotecan (180 mg/m²) with 5‐fluorouracil (400 mg/m² bolus) and leucovorin (125 mg/m²) followed by 5‐FU (1200 mg/m² infusion over 48 h) every 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irinotecan and 5‐fluorouracil treatment
Number of subjects: 40
Study: 11716046

Group type: EXPERIMENTAL
Intervention: 21-gauge needles
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25-gauge needles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 21-gauge and 25-gauge needles
Number of subjects: 50
Study: 9150480

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) treatment
Number of subjects: 19
Study: 7950184

Group type: EXPERIMENTAL
Intervention: Kuiyangqing Pill (KYQP) for EHS group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bismuth aluminate tablets (control) for EHS group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Kuiyangqing Pill (KYQP) for DCS group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bismuth aluminate tablets (control) for DCS group
Number of subjects: 80
Study: 3109990

Group type: EXPERIMENTAL
Intervention: 150 micrograms of rioprostil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 micrograms of rioprostil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 600 micrograms of rioprostil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All doses of rioprostil
Number of subjects: 8
Study: 29218735

Group type: EXPERIMENTAL
Intervention: Fibre Retention Osseous Resective Surgery (FibReORS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Osseous Resective Surgery (ORS)
Number of subjects: 13
Study: 28695586

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment group (pressure-controlled ventilation set at 16 cmH2 O with 10 cmH2 O positive end-expiratory pressure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (volume-controlled ventilation with 5 cmH2 O positive end-expiratory pressure, low tidal volumes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24972907

Group type: EXPERIMENTAL
Intervention: Clinical case management (CM) programme
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment programme (STP)
Number of subjects: 150
Study: 23296827

Group type: EXPERIMENTAL
Intervention: Tannin diet (20 g DM of alfalfa hay/kg BW supplemented with 50 g of quebracho/kg DM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet (20 g DM of alfalfa hay/kg BW)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tannin diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 16
Study: 21723792

Group type: COMPARATOR
Intervention: Paclitaxel and Bevacizumab (PB)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Paclitaxel, Bevacizumab, and Gemcitabine (PB+G)
Number of subjects: 187
Study: 19491981

Group type: EXPERIMENTAL
Intervention: Aspherical IOLs (Acrysof IQ, Tecnis Z9001)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Spherical IOL (Acrysof Natural)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acrysof IQ and Tecnis Z9001
Number of subjects: 57
Study: 17111014

Group type: EXPERIMENTAL
Intervention: Caffeine (CAFF; 5 mg/kg body mass)
Number of subjects: 18
Study: 15679253

Group type: EXPERIMENTAL
Intervention: Cisplatin and its derivatives with radiation therapy
Number of subjects: 0
Study: 11543992

Group type: EXPERIMENTAL
Intervention: Alcohol group (alcoholic drink)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Placebo group (non-alcoholic drink told to contain alcohol)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (non-alcoholic drink told to contain no alcohol)
Number of subjects: 61
Study: 9485982

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (0.09 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 8203424

Group type: EXPERIMENTAL
Intervention: Modified biophysical profile
Number of subjects: 2774

Group type: COMPARATOR
Intervention: Contraction stress test
Number of subjects: 2774

Group type: COMPARATOR
Intervention: Biophysical profile
Number of subjects: 2774
Study: 3540140

Group type: EXPERIMENTAL
Intervention: Aminoglycoside therapy (gentamicin, tobramycin, amikacin)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Elevated maximal and mean peak aminoglycoside concentration/MIC ratios
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Maximal peak concentration/MIC ratio
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Peak concentration/MIC ratios
Number of subjects: 236
Study: 30544227

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 41
Study: 30691515

Group type: EXPERIMENTAL
Intervention: Triangulating Stapling (TS) method
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Functional End-to-End Stapling (FEES) method
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Overall postoperative morbidity
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Incidence of anastomotic leakage, aspiration pneumonia, or reflux esophagitis
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using FACT-E
Number of subjects: 125
Study: 29030199

Group type: EXPERIMENTAL
Intervention: 200 μg iodine orally once a day until delivery
Number of subjects: 832

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 832
Study: 26319820

Group type: EXPERIMENTAL
Intervention: Low-fat, phytosterol-supplemented milk (2.24 gr of plant sterols daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Low-fat conventional milk
Number of subjects: 67
Study: 23810643

Group type: EXPERIMENTAL
Intervention: 400 mL of beer
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 800 mL of dealcoholized beer
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 67 mL of vodka and 733 mL water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 17
Study: 21343498

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 44

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 44